“Menopause hormone therapy is safe and worth it for most women.”
Hormone therapy is usually safe and worth it for women with bothersome symptoms who start before 60 or within 10 years of menopause.
If hot flashes, night sweats or vaginal symptoms are affecting your life and you are under 60 or within 10 years of menopause, hormone therapy is worth a real conversation, not something to fear by default. Women who start later, or who have certain health histories, face a less favorable balance, so for them the choice needs a closer look at other options.
If menopause symptoms affect your life, ask for an individualized discussion of hormone and nonhormone options, including the formulation, duration and follow-up plan.
Safety note: Systemic and local hormone treatments have different risk profiles. Personal history of breast or endometrial cancer, unexplained bleeding, blood clots, stroke, heart disease, liver disease and whether the uterus is present can change the plan.
Talk to a healthcare professional if: menopause symptoms such as hot flashes, night sweats or vaginal dryness are affecting your sleep, work or daily life, or you are already on hormone therapy and want to review whether to continue.
Hormone therapy is the most effective treatment for hot flashes and can prevent bone loss. For many healthy women younger than 60 or within 10 years of menopause who have bothersome symptoms and no contraindications, benefits can outweigh risks. The answer changes with symptoms, age, timing, formulation and health history.
Hormone therapy is usually safe and worth it for women with bothersome symptoms who start before 60 or within 10 years of menopause. For women who start after 60 or more than 10 years after menopause, the balance is less favorable because the absolute risks of heart disease, stroke, blood clots and dementia are higher. The type, dose, route and length of treatment also change the risks.
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. DOI: 10.1097/GME.0000000000002028
- Manson JE, Aragaki AK, Rossouw JE, et al.; WHI Investigators. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938. DOI: 10.1001/jama.2017.11217
- US Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. 2026